PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.

Inclusion Criteria:

• International Prostate Symptom Score (IPSS) ≥ 8
• Gleason Grade Group 1-3
• Prostate-specific Antigen (PSA) ≤20ng/mL
• Cancer stage less than or equal to T2c

Exclusion Criteria:

• Patients with previous surgical treatment of benign prostatic hyperplasia
• MRI evidence of extracapsular extension of cancer
• Any severe illness that would prevent complete study participation or confound study results